Basit öğe kaydını göster

dc.contributor.authorGedikoglu, Gokhan
dc.contributor.authorÜNER, AYŞEGÜL
dc.contributor.authorSaglam, Arzu
dc.contributor.authorDemiroz, Ahu Senem
dc.contributor.authorKUZU, Işınsu
dc.contributor.authorAkyol, Aytekin
dc.contributor.authorUzun, Sarp
dc.contributor.authorOzcan, Ozge
dc.contributor.authorIsik, Aynur
dc.date.accessioned2021-12-10T09:54:35Z
dc.date.available2021-12-10T09:54:35Z
dc.identifier.citationUzun S., Ozcan O., Isik A., Saglam A., Gedikoglu G., Demiroz A. S. , KUZU I., ÜNER A., Akyol A., "Loss of CTNNB1 exon 3 in sclerosing angiomatoid nodular transformation of the spleen", VIRCHOWS ARCHIV, 2021
dc.identifier.issn0945-6317
dc.identifier.othervv_1032021
dc.identifier.otherav_1bbb48ba-ae2c-4e6f-a896-5ef9a1cc24d5
dc.identifier.urihttp://hdl.handle.net/20.500.12627/168756
dc.identifier.urihttps://doi.org/10.1007/s00428-021-03064-y
dc.description.abstractSclerosing angiomatoid nodular transformation (SANT) is a rare vascular lesion of the spleen. Although several hypotheses have been suggested, the etiopathogenesis of SANT remains unknown. It is also unclear whether SANT is a reactive or a neoplastic lesion. Since CTNNB1 (beta-catenin gene) exon 3 mutations were frequently detected in some rare fibrovascular lesions, we aimed to investigate the presence of oncogenic CTNNB1 mutations in SANT cases. For this purpose, 7 cases of SANT with typical histopathological features were retrieved. First, the presence of CTNNB1 exon 3 alterations was examined with a recently described immunohistochemistry-based method. Then, the findings were confirmed with polymerase chain reaction (PCR), reverse transcription PCR (RT-PCR), and Sanger sequencing. In all cases, immunochemistry of beta-catenin gave a staining pattern that was suggestive of exon 3 alteration; however, no missense mutations were found in any case at the CTNNB1 exon 3 hotspot region. Subsequently, we screened for large interstitial deletions of CTNNB1 exon 3 which revealed short PCR products in three cases. Sequencing confirmed that these cases had large interstitial deletions, resulting in loss of the entire exon 3 of CTNNB1. In the remaining four cases, loss of exon 3 was documented at the cDNA level, although genomic deletion was not identified. These results demonstrate that loss of CTNNB1 exon 3 and stabilization of beta-catenin with activation of Wnt signaling pathway might have a significant role in the pathogenesis of SANT. Through this study, we provided important evidence for the neoplastic nature and pathogenesis of this disorder.
dc.language.isoeng
dc.subjectCerrahi Tıp Bilimleri
dc.subjectPatoloji
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectHistology
dc.subjectPathology and Forensic Medicine
dc.subjectBiochemistry (medical)
dc.subjectHealth Sciences
dc.subjectSağlık Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectBiyoloji ve Biyokimya
dc.subjectPATOLOJİ
dc.subjectBiyokimya
dc.subjectTemel Tıp Bilimleri
dc.subjectTıp
dc.titleLoss of CTNNB1 exon 3 in sclerosing angiomatoid nodular transformation of the spleen
dc.typeMakale
dc.relation.journalVIRCHOWS ARCHIV
dc.contributor.departmentHacettepe Univ Transgen Anim Technol Res & Applic , ,
dc.contributor.firstauthorID2533680


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster